scholarly journals Anticancer Activity of Continentalic Acid in B-Cell Lymphoma

Molecules ◽  
2021 ◽  
Vol 26 (22) ◽  
pp. 6845
Author(s):  
Byeol-Eun Jeon ◽  
Chan-Seong Kwon ◽  
Ji-Eun Lee ◽  
Keumok Moon ◽  
Jaeho Cha ◽  
...  

Aralia continentalis has been used in Korea as a folk remedy for arthralgia, rheumatism, and inflammation. However, its anti-lymphoma effect remains uncharacterized. Here, we demonstrate that A. continentalis extract and its three diterpenes efficiently kill B-lymphoma cells. Our in vitro and in vivo results suggest that the cytotoxic activities of continentalic acid, a major diterpene from A. continentalis extract, are specific towards cancer cells while leaving normal murine cells and tissues unharmed. Mechanistically, continentalic acid represses the expression of pro-survival Bcl-2 family members, such as Mcl-1 and Bcl-xL. It dissociates the mitochondrial membrane potential, leading to the stimulation of effector caspase 3/7 activities and, ultimately, cell death. Intriguingly, this agent therapeutically synergizes with roflumilast, a pan-PDE4 inhibitor that has been successfully repurposed for the treatment of aggressive B-cell malignancies in recent clinical tests. Our findings unveiled that A. continentalis extract and three of the plant’s diterpenes exhibit anti-cancer activities. We also demonstrate the synergistic inhibitory effect of continentalic acid on the survival of B-lymphoma cells when combined with roflumilast. Taken in conjunction, continentalic acid may hold significant potential for the treatment of B-cell lymphoma.

2020 ◽  
Vol 12 (10) ◽  
pp. 1524-1534
Author(s):  
Zhiqiang Peng ◽  
Jianping Xiong ◽  
Hanzhi Dong ◽  
Wuping Li

The β-cyclodextrin (β-CD) is coupled with polyethyleneimine (PEI 600 Da) to produce a polymer nanocarrier material (PyD-W) with good biocompatibility and high transfection rate. First, the test was performed to study the influence of different factors on the transfection efficiency of PyD-W materials in terms of cell type and transfection system. Then the effect of adding wheat germ agglutinin on the material-cell membrane binding when transfecting cells by PyD-W materials was studied. The influence of temperature and cell phagocytosis inhibitors on the entire transfection process were taken into consideration at the same time. In the end, the escape ability of PyD-W material carrying plasmid DNA in lysosomes was studied. After analyzing the performance of PyD-W material transfected cells, the appropriate transfection staining conditions was selected to be applied in the study of the inhibitory properties of mouse B-cell lymphoma cells. In the experiment, the results showed that the cell type had a great influence on the material. The N/P ratio should not be set too high. Prolong the transfecting and fostering time appropriately could increase the transfection efficiency. The addition of wheat germ lectin would significantly reduce the enrichment ability on the cell surface of plasmid DNA carried by PyD-W. Increasing the temperature could also increase the transfection efficiency of PyD-W materials, cell phagocytosis inhibitors would not have a significant impact on transfection, and the accumulation of PyD-W materials in lysosomes would be gradually released from lysosomes with time going by. According to the above results, PyD-W carrying plasmid DNA was transfected into mouse B lymphoma cells and normal B cells using similar transfection methods. The results show that B lymphoma cells (38B9) corresponded significant mRNA levels is lower than the mRNA level of normal B cells (P < 0.05). It is detected by cell count and CCK-8 kit that the growth of cells in the group overexpressing PyD-W is significantly inhibited (P < 0.01).


Blood ◽  
2001 ◽  
Vol 97 (5) ◽  
pp. 1392-1398 ◽  
Author(s):  
Maria-Ana Ghetie ◽  
Helen Bright ◽  
Ellen S. Vitetta

In 1997, a chimeric anti-CD20 monoclonal antibody (mAb) (Rituxan) was approved for the treatment of low-grade/follicular B-cell lymphoma. Rituxan has a long half-life and low immunogenicity, and it mediates effector function. Rituxan induces apoptosis in some tumor cell lines in vitro. Previous studies with mAbs that react with neoplastic B cells have demonstrated that homodimers of immunoglobulin G ([IgG]2) often inhibit cell growth more effectively than their monomeric (IgG)1counterparts. In this study, the ability of IgG or F(ab′)2 homodimers vs monomers of Rituxan were compared for their ability to inhibit the growth of several different B-lymphoma cell lines in vitro. It was found that homodimers of Rituxan had superior antigrowth activity in vitro and that F(ab′)2 homodimers were the most active. Homodimers, but not monomers, of Rituxan induced both apoptosis and necrosis of several B-cell lymphoma lines in vitro; the inhibition of cell growth was not dependent upon the presence of Fc receptors or upon 10-fold or greater differences in the density of CD20 on the target cells. Rituxan homodimers, compared with monomers, also rendered drug-resistant CD20+ B-lymphoma cells more sensitive to chemotherapeutic agents and synergized with an anti-CD22 immunotoxin in vitro.


Blood ◽  
2003 ◽  
Vol 102 (2) ◽  
pp. 605-612 ◽  
Author(s):  
Katrin U. Lundin ◽  
Peter O. Hofgaard ◽  
Hilde Omholt ◽  
Ludvig A. Munthe ◽  
Alexandre Corthay ◽  
...  

AbstractImmunoglobulin (Ig) variable (V) region idiotypes (Id's) are highly tumor-specific antigens produced by B-lymphoma cells and are promising targets for immunotherapy. Id vaccination has proven effective in experimental mouse models and may possibly prevent recurrence of B lymphomas in humans. It has previously been shown that anti-Id antibodies protect against B-cell lymphoma in the absence of T cells. We here demonstrate in a T-cell–receptor transgenic mouse model that the contrary is also true: Id-specific CD4+ T cells can protect against Id+ B-lymphoma cells in the absence of B cells, antibodies, and CD8+ T cells. Moreover, Id-specific CD4+ T cells have a curative potential since they could be transferred as late as 17 days after subcutaneous tumor cell injection of severe combined immunodeficiency (SCID) mice and still abrogate tumor development in about 50% of mice. Such mice undergo an acute inflammatory swelling with infiltration of neutrophils at the site of tumor injection, which subsides over weeks, with some mice cured and delayed emergence of lymphomas in other mice. Adoptively transferred CD4+ T cells accumulated in the tumor and were activated (CD69+). In vitro experiments demonstrated that memory, but not naive, Id-specific CD4+ T cells kill Id+ B-lymphoma cells. The results show that Id-specific CD4+ T cells, in the absence of antibodies home to subcutaneous Id+ B lymphoma, become activated, induce inflammation, and prevent tumor development.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2942-2942
Author(s):  
Zhong Zheng ◽  
Peng-Peng Xu ◽  
Li Wang ◽  
Hui-Jin Zhao ◽  
Wei Li Zhao

Abstract MicroRNAs (miRs), a class of 19- to 23-nucleotide non-coding RNA molecules, are involved in tumorigenesis by regulating tumor cells and microenvironment. Our study revealed serum miR21 expression in a large cohort of B-cell lymphoma patients and the biological function of miR21 both in vitro and in vivo. Comparing with healthy volunteers, serum miR21 was significantly increased in patients with B-cell lymphoma (Figure 1A). As revealed by immunohistochemistry in 50 tumor samples of DLBCL, CD31-positive microvessels were more frequently observed in high miR21 group than in low miR21 group (Figure 1B). High miR21 expression patients displayed more peripheral blood Treg cells than low miR21 expression patients, instead of natural killer (NK) cells (Figure 1C). We futher study the biological function of miR21, B-lymphoma cell SU-DHL-4 were transfected with miR21 mimics and treated with chemotherapeutic agents. Under the monoculture condition, as compared to the control mimics, ectopic expression of miR21 significantly diminished the cytotoxic effect of doxorubicin and cisplatin, but sensitized lymphoma cells to ABT-199. Under the direct co-culture system, mimicking lymphoma microenvironment, miR21 overexpression resulted in lymphoma cell resistance to chemotherapeutic agents, but sensitivity to ABT-199 in the direct co-culture system. ABT-199 remarkably downregulated miR21 expression in both the monoculture system and the direct co-culture system, irrespective to Bcl-2 expression. To clarify the underlying mechanism of miR21-mediated sensitization of ABT-199 on B-cell lymphoma, we studied the effect of miR21 on HUVEC sorted from the direct co-culture system. Co-culturing with miR21-overexpressing lymphoma cells significantly stimulated HUVEC growth, which was retarded by ABT-199 (Figure 2A). As detected by ELISA, VEGFA was increased by miR21 transfection and reduced by ABT-199 in both control siRNA-transfected HUVEC and Bcl-2 siRNA-transfected HUVEC (Figure 2B). Accordingly, similar changes of tube formation and endothelial cell migration towards lymphoma cells were present (Figure 2C). We hereafter studied the effect of miR21 on Treg cells sorted from the direct co-culture system. Consistent with change of VEGFA, co-culturing with miR21-overexpressing lymphoma cells significantly increased VEGFR2 expression on Treg cells, which were decreased by ABT-199 (Figure 2D). ABT-199-induced downregulation of VEGFA/VEGFR2 signaling was associated with Treg cell growth inhibition, resulting in reduction of immunosuppressive cytokine TGF-¦Â and molecule IL-2 (Figure 2E and 2F). In the direct co-culture system, miR21 overexpression induced ICOS expression on Treg cells and ICOSL expression on HUVEC and, both of which were inhibited by ABT-199 (Figure 3A). To confirm the role of ICOS/ICOSL axis, antibody against ICOS was added to the direct co-culture system. Pharmacological inhibition of ICOS/ICOSL interaction significantly abrogated the sensitivity of miR21-overexpressing cells to ABT-199, as well as HUVEC and Treg cell growth (Figure 3B). Blockade of ICOS/ICOSL also interfered the action of ABT-199 on VEGFA/VEGFR2 signaling between Treg cells and endothelial cells (Figure 3C). Murine xenograft model was established with subcutaneous injection of B-lymphoma cells, ABT-199 particularly retarded the growth of miR21-overexpressing tumors, consistent with the inhibition of ICOS/ICOSL axis, VEGFA/VEGFR2 signaling, tumor angiogenesis and Treg cell growth. Collectively, these data demonstrated that miR21 plays an oncogenic role in B-cell lymphoma by modulating tumor microenvironment and supported clinical rationale for using miR21 as a biomarker to select chemoresistant B-lymphoma patients who may benefit from treatments containing ABT-199. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 5176-5176
Author(s):  
Suresh Veeramani ◽  
Chris Dahle ◽  
George Weiner

Abstract Abstract 5176 The effect of complement on the immune system is complex and includes inhibition of aspects of the immune response. For example, we previously reported that C3b can inhibit the ability of mAb to activate NK cell-mediated antibody-dependent cellular cytotoxicity and that polymorphisms in C1q associated with lower C1q levels correlate with better therapeutic outcome. Polymorphisms in C5 and C9 complement components have also been shown to be associated with lymphoma risk. The current studies were designed to assess whether complement components may exert their inhibitory effects through the immune regulatory network, such as that mediated by T regulatory (Treg) cells. Peripheral Blood Mononuclear Cells (PBMCs) from healthy donors were co-cultured with Raji B cell lymphoma cells for 48 hours in the presence of unmodified autologous human serum or complement-depleted serum [heat-inactivated (HI) or cobra-venom factor (CVF)-treated serum]. Cells were stained with anti-CD3-APC-Cy7, CD4-PE-Cy7, CD25-PerCP-Cy5.5 and Foxp3-APC and the percent of CD4+ T-cells that were CD25highFoxp3+ (henceforth referred to as Tregs) determined. The ability of cells cultured in this manner to inhibit granzyme B expression in PHA-activated CD8+ autologous T cells was also determined. Tregs were not induced when PBMCs were cultured without Raji cells regardless of whether the cells were cultured in serum (data not shown). However, PBMCs co-cultured with Raji B lymphoma cells showed significantly higher percentages of Tregs in the presence of unmodified human serum (*p=0.0387) when compared to HI or CVF-treated human serum (**p=0.0370 and 0.0227, respectively) (Fig. 1). Tregs enriched from PBMCs cultured with unmodified human serum and Raji cells also showed an increase in immunosuppressive function, as determined by their inhibitory effect on PHA-induced GrzB expression by autologous CD8+ T cells (*p=0.0029) (Fig. 2).unmodified or complement-inactivated humanunmodified or complement-inactivated human We conclude that complement enhances generation of Treg cells induced by B lymphoma cells as indicated by both phenotypic and functional studies. Ongoing studies are exploring the role of individual complement components in Treg induction, and the possibility of using complement depletion as a strategy to boost immune responses against lymphoma. Disclosures: No relevant conflicts of interest to declare.


2017 ◽  
Vol 1 (27) ◽  
pp. 2712-2723 ◽  
Author(s):  
Pradeep Bangalore-Prakash ◽  
Laura L. Stunz ◽  
Nurbek Mambetsariev ◽  
Amy L. Whillock ◽  
Bruce S. Hostager ◽  
...  

Key Points Expression of the Epstein-Barr virus–encoded oncoprotein LMP1 leads to sequestration of TRAF3 in B-lymphoma cells. This sequestration inhibits TRAF3-negative regulation of prosurvival membrane, cytoplasmic, and nuclear signaling events in the B cell.


Hemato ◽  
2021 ◽  
Vol 2 (2) ◽  
pp. 368-381
Author(s):  
Ichiro Hanamura ◽  
Susumu Suzuki ◽  
Akinobu Ota ◽  
Satsuki Murakami ◽  
Akira Satou ◽  
...  

The clinical and biological significance of programmed death-1 (PD-1) expression by B-lymphoma cells is largely unknown. Here, using multicolor immunofluorescent staining (MC-IF), we investigated PD-1 and PD-L1 expression in PAX5+ (B-lymphoma), CD68+ (macrophage), or CD3+ (T-cell) cells in formalin-fixed, paraffin-embedded samples of 32 consecutive patients with de novo diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus chemotherapy. PD-1- and PD-L1-expressing PAX5+ cells were observed in 59% and 3% of the patients, respectively. PD-1-expressing CD3+ lymphocytes and PD-L1-expressing CD68+ macrophages were observed in 89% and 86% of the patients, respectively. PD-L1 expression on PAX5+ lymphoma cells or CD68+ macrophages and PD-1 expression on CD3+ lymphocytes were not correlated with prognosis. However, patients with PD-1 expression on lymphoma cells showed shorter progression-free survival than those lacking PD-1-expressing lymphoma cells (p = 0.033). Furthermore, genetically modified PD-1-knockout human B-lymphoma VAL cells showed reduced cell growth and migration, and decreased S6 kinase phosphorylation than VAL/mock cells. Our data suggest that PD-1 expression on DLBCL cells detected by MC-IF was associated with poor prognosis and cell-intrinsic PD-1 signaling was related with cell growth and migration in a subpopulation of B-cell lymphoma. These findings may allow the development of distinct DLBCL subtypes affecting prognosis.


2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
J. Devin ◽  
T. Cañeque ◽  
Y.‐L. Lin ◽  
L. Mondoulet ◽  
J.‐L. Veyrune ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document